论文部分内容阅读
FDA批准来那度胺用于治疗复发性难治性套细胞淋巴瘤Celgene Corporation公司近日宣布,美国FDA已批准Revlimid(Ienalidomide,来那度胺)用于治疗既往接受过2种药物(其中一种包括硼替佐米)治疗后复发或进展的套细胞淋巴瘤患者。此项批准主要基于134例复发性难治性套细胞淋巴瘤患者的Ⅱ期临床试验结果(代号:MCL-001,临床编号:NCT00737529)。这些患者之前单用或联用过利妥昔单抗、环磷酰胺、一种蒽环类抗生素(或米托蒽
FDA Approves Lenalidomide for the Treatment of Relapsed Refractory Mantle Cell Lymphoma Celgene Corporation recently announced that the FDA has approved the use of Revlimid (Ienalidomide, lenalidomide) in the treatment of previously received 2 drugs Including bortezomib) patients with relapsed or advanced mantle cell lymphoma. This approval is based primarily on Phase II clinical trial results of 134 patients with relapsed / refractory mantle cell lymphoma (Code: MCL-001, Clinical No .: NCT00737529). These patients have been previously used alone or in combination with rituximab, cyclophosphamide, an anthracycline (or mitoxantrone